224 results about "Drug vehicle" patented technology

A hygroscopic pharmaceutical composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and an antiinfective agent. A foamble pharmaceutical carrier includes about 50% to about 98% of a polar solvent selected from the group consisting of a polyol and PEG; 0% to about 48% of a secondary polar solvent; about 0.2% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent; and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

A composition including a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier. The amount of the compound present is effective to control appetite in a human. Also disclosed is a method for controlling appetite and for reducing food intake in a human by administering to the human a composition comprising a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier.

The present invention teaches a foamable pharmaceutical carrier comprising a benefit agent, selected from the group consisting of a dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected from the group consisting of at least one surface-active agent; at least one polymeric agent and mixtures thereof; a solvent selected from the group consisting of water, a hydrophilic solvent, a hydrophobic solvent, a potent solvent, a polar solvent, a silicone, an emollient, and mixtures thereof, wherein the benefit agent, stabilizer and solvent are selected to provide a composition that is substantially resistant to aging and to phase separation and or can substantially stabilize other active ingredients. The invention further relates to a foamable composition further containing a liquefied hydrocarbon gas propellant.

Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

A composition including a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier. The amount of the compound present is effective to control appetite in a human. Also disclosed is a method for controlling appetite and for reducing food intake in a human by administering to the human a composition comprising a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier.

The preparation method includes the following steps: modifying hepatic target compound onto degradable polymer (chitosan, polylysine, glucosan, agar, polyglutamic acid-benzyl ester, polyalanine) with biological compatibility, and adopting ion exchange or ultrasonic emulsification process to obtain the invented nano hepatic target bio-degradable medicine carrier material. The hepatic target nano particle solution has good target performance for liver, the medicine enriched rate in the liver can be up to 75%, and its slowly-released administration can be up to above 15 days.

The invention discloses a conjugate of fatty aminoacyl alexan, preparation and application in anti-tumor thereof. The invention also discloses a pharmacosome of the conjugate of fatty aminoacyl alexan, preparation thereof, and its applicant in anti-tumor and preparation of target medicine material of microemulsion, lipid medicine carrier. In comparison with alexan, the inventive conjugate of fatty aminoacyl alexan has a strong transmembrane ability, high bioavailability, long halflife, and amphipathic nature. It is demonstrated that the inventive compound and pharmacosome have great anti-tumor activity.

Methods and compositions for enhancing transdermal delivery of a bioactive agent. The method contains the step of applying to a skin tissue an effective amount of a composition comprising: (a) a drug vehicle; (b) a bioactive agent encapsulated within the drug vehicle; (c) a plurality of proteolytic enzyme molecules conjugated onto the surface of the drug vehicle; and (d) a pharmaceutically acceptable carrier, for a period of time effective to deliver the bioactive agent across the skin tissue at a desired dosage.

A hair treatment composition for topical application to the skin and / or hair, comprising partially hydrolyzed fucoidan and a pharmaceutical carrier. The composition may contain further additives. The carrier may be hydrophyllic or anhydrous. The composition may also include natural components such as honey and / or mangosteen. The composition may also include flavonoids, analgesics, radiation protecting agents, and / or anti-oxidants.

The present invention teaches a foamable pharmaceutical carrier comprising a benefit agent, selected from the group consisting of a dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected from the group consisting of at least one surface-active agent; at least one polymeric agent and mixtures thereof; a solvent selected from the group consisting of water, a hydrophilic solvent, a hydrophobic solvent, a potent solvent, a polar solvent, a silicone, an emollient, and mixtures thereof, wherein the benefit agent, stabilizer and solvent are selected to provide a composition that is substantially resistant to aging and to phase separation and or can substantially stabilize other active ingredients. The invention further relates to a foamable composition further containing a liquefied hydrocarbon gas propellant.

The present invention includes a method for reducing viral, bacterial, protozoan, fungal and other parasitic contamination from a biological solution. Biological solutions include, but are not limited to, solutions comprising blood, a blood component, cell culture or a component of a cell culture. In accordance with the present invention, there is provided, a method of inactivating a pathogen in blood or blood product in a container, comprising contacting at least one of said blood, blood product and container with a composition of the present invention. In accordance with the present invention, there is provided, a medical device comprising at least a surface treated with an anti-pathogenic composition of the present invention or containing at least an anti-pathogenic composition of present invention. In accordance with the present invention, there is provided, an anti-pathogenic composition for use in disinfecting fluids and biological tissues and surfaces contaminated with fluids and / or biological tissues, which comprises an anti-pathogenic amount of at least one quaternary ammonium compound in association with an acceptable carrier. A preferred anti-pathogenic composition of the present invention further comprises a bisguanidine compound. In accordance with the present invention, there is provided a method for inhibiting in vitro or ex vivo infection or replication of human immunodeficiency virus in a biological fluid, comprising treating said biological fluid with an effective inhibiting amount of a bis-guanidine compound or a derivative thereof, and at least one quaternary ammonium compound in combination with a pharmaceutically carrier, such as DMSO.